Impact of high-power short-duration atrial fibrillation ablation technique on the incidence of silent cerebral embolism: a prospective randomized controlled study

Table 7 Univariable and multivariable logistic regression analysis of periprocedural SCE

Variables	Univariable regression analysis			Backward stepwise multivariable regression analysis
Variables	OR	95% CI	P value	OR	95% CI	P value	Elimination step
Age	1.036	0.998–1.075	0.061	0.998	0.947–1.052	0.947	3
Persistent AF	2.690	1.180–6.131	0.019	2.689	1.132–6.387	0.025	In the equation
CHA₂DS₂-VASc score	1.570	1.154–2.136	0.004	1.568	1.143–2.150	0.005	In the equation
Cardioversion	2.354	0.984–5.630	0.054	1.031	0.273–3.901	0.964	2
Coronary artery disease	2.22	1.045–7.092	0.040	1.960	0.678–5.637	0.214	7
Hypertension^a	4.105	1.765–9.547	0.001	——	——	——	——
LAD (mm)	1.092	1.000–1.194	0.051	0.970	0.859–1.095	0.621	5
PVI plus	2.376	1.049–5.382	0.038	1.271	0.403–4.012	0.682	4
Initial ACT before energy delivery	0.999	0.990–1.008	0.851	——	——	——	——
Mean ACT during procedure	0.999	0.987–1.011	0.841	——	——	——	——
Procedure time	1.007	0.999–1.014	0.090	1.003	0.994–1.012	0.491	6
Radiofrequency time	1.002	0.971–1.034	0.901	——	——	——	——
Irrigation volume	1.000	0.999–1.002	0.599	——	——	——	——

ACT activated clotting time, AF atrial fibrillation, LAD left atrial diameter, PVI pulmonary vein isolation, SCE silent cerebral embolism
^aAs hypertension was contained within the CHA₂DS₂-VASc score, even the p values were less than 0.1 in the univariable analysis; it was not repeatedly entered in the multivariable logistic regression analysis to avoid potential interactions between hypertension and the CHA₂DS₂-VASc score

ISSN: 1741-7015